



MAIL STOP - PCT
Docket No.: 27646U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: PALMER

Art Unit: XX

Appl. No.: 10/592,947

Examiner: XX

Appl. Filing Date: September 15, 2006

Confirm. No.: XX

Intl. Appl. No.: PCT/EP2005/051269

Intl. Appl. Filing Date: March 18, 2005

For: **7,8,9,10-TETRAHYDRO-IMIDAZO[2,1-A]ISOCHINOLINES**

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

1. Information Disclosure Statement;
2. PTO Form-1449 with 7 references cited; and
3. Copies of 6 of the 7 references cited.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,
NATH & ASSOCIATES PLLC

December 4, 2006


Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

Le



MAIL STOP - PCT
Docket No.: 27646U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: PALMER

Art Unit: XX

Appl. No.: 10/592,947

Examiner: XX

Appl. Filing Date: September 15, 2006

Confirm. No.: XX

Intl. Appl. No.: PCT/EP2005/051269

Intl. Appl. Filing Date: March 18, 2005

For: 7,8,9,10-TETRAHYDRO-IMIDAZO[2,1-A]ISOCHINOLINES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

a. [XXX] The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. [] The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

- [] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
- [] ii. a check in the amount required by 37 C.F.R. 1.17(p).

- c. [] The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.
- [] Certification report(e) below; and
- [] a check in the amount as required by 1.17(p).
- d. [] The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.
- e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]
- [] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
- or
- [] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- or
- [] Appropriate certification is attached.
- f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

g. [XX] Copies of the documents are attached herewith with a completed PTO Form-1449.

or

[] Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or


[XXX] Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

December 4, 2006


Gary M. Nath, Reg. No. 26,965
Sheldon M. McGee, Reg. No. 50,454
Customer No. 34375

Le



MAIL STOP - PCT
Docket No.: 27646U

PTO FORM-1449

**INFORMATION DISCLOSURE
CITATION**

Inventor: PALMER

Appl. No.:	Intl. Appl. No.:
10/592,947	PCT/EP2005/051269

Art Unit: XX

Appl. Filing Date:	Intl. Appl. Filing Date:
September 15, 2006	March 18, 2005

Examiner: XX

Confirm. No.: XX

U. S. PATENT DOCUMENTS

Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filed Date
	A1	4,468,400	8/28/1984	Gold et al.	12/20/1982
	A2				
	A3				
	A4				
	A5				
	A6				
	A7				
	A8				

FOREIGN PATENT DOCUMENTS

Exam. Initial		Document No.	Public. Date	Country	Translation
	A9	2005/077949 A1	8/25/2005	WO	N/A
	A10	03/014123 A1	2/20/2003	WO	N/A
	A11	2005/058325 A1	6/30/2005	WO	N/A
	A12	2005/090358 A2	9/29/2005	WO	N/A
	A13				
	A14				
	A15				
	A16				
	A17				
	A18				

OTHER

(Including Author, Title, Date, Pertinent Pages, etc.)

Exam. Initial		
	A19	Kaminski, J.J., et al., "Antiulcer Agents. 1. Gastric Antisecretory and Cytoprotective Properties of Substituted Imidazo[1,2-a]pyridines", <i>J. Med. Chem.</i> , Vol. 28, pg. 876-892, (1985).
	A20	Kaminski, J.J., et al., "Antiulcer Agents. 6. Analysis of the in Vitro Biochemical and in Vivo Gastric Antisecretory Activity of Substituted Imidazo[1,2-a]pyridines and Related Analogues Using Comparative Molecular Field Analysis and Hypothetical Active Site Lattice Methodologies", <i>J. Med. Chem.</i> , Vol. 40, pg. 427-436, (1997).
	A21	
	A22	

Examiner _____ Date Considered _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.